<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARVEDILOL
                 - carvedilol tablet, film coated </strong><br>St Marys Medical Park Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">      These highlights do not include all the information needed to use carvedilol safely and effectively. See full prescribing information for carvedilol tablets, USP.<br><br>Carvedilol Tablets, USP<br>        Initial U.S. Approval: 1995  <br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Major Surgery <a href="http://pragmaticdata.com/spl/form/#Section_5.9">(5.9)</a>  October 2010<br>Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span> <a href="http://pragmaticdata.com/spl/form/#Section_5.15">(5.14)</a>  January 2011 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of:  </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left ventricular dysfunction</span> following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in clinically stable patients (<a href="http://pragmaticdata.com/spl/form/#Section_1.2">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <a href="http://pragmaticdata.com/spl/form/#Section_1.3">(1.3)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">									Take with food. Individualize dosage and monitor during up-titration. (<a href="#Section_2">2</a>)								 </p>
<ul class="Disc">
<li>										<span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left ventricular dysfunction</span> following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>: Start at 6.25 mg twice daily and increase to 12.5 mg then  25 mg twice daily after intervals of 3 to 10 days. A lower starting dose or slower titration may be used. (<a href="#Section_2.2">2.2</a>)									</li>
<li>										<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks. (<a href="#Section_2.3">2.3</a>)									</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 3.125 mg, 6.25 mg, 12.5 mg, or 25 mg (<a href="#Section_3">3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or related bronchospastic conditions (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
<li>Second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick sinus syndrome</span> (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (unless permanent pacemaker in place) (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
<li>Patients in <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> requiring the use of IV inotropic therapy. (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="http://pragmaticdata.com/spl/form/#Section_2.4">2.4</a>, <a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to any component of this medication or other medications containing carvedilol. (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Acute exacerbation of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> upon cessation of therapy: Do not abruptly discontinue. <a href="http://pragmaticdata.com/spl/form/#Section_5.1">(5.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>/<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> may occur. Reduce the dose as needed. (<a href="http://pragmaticdata.com/spl/form/#Section_5.2">5.2</a>, <a href="http://pragmaticdata.com/spl/form/#Section_5.3">5.3</a>, <a href="http://pragmaticdata.com/spl/form/#Section_5.4">5.4</a>)</li>
<li>Non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">allergic bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>): Avoid β-blockers. (<a href="http://pragmaticdata.com/spl/form/#Section_4">4</a>) However, if deemed necessary, use with caution and at lowest effective dose. (<a href="http://pragmaticdata.com/spl/form/#Section_5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>: Monitor glucose as β-blockers may mask symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or worsen <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. (<a href="http://pragmaticdata.com/spl/form/#Section_5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse events (<a href="http://pragmaticdata.com/spl/form/#Section_6.1">6.1</a>): </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left ventricular dysfunction</span> following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (≥10%): <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span></li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (≥5%): <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
</ul>
<p class="Highlighta"><br><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>CYP P450 2D6 enzyme inhibitors may increase and rifampin may decrease carvedilol levels. (<a href="#Section_7.1">7.1</a>, <a href="#Section_7.5">7.5</a>)    </li>
<li>Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. (<a href="#Section_7.2">7.2</a>)    </li>
<li>Cyclosporine or digoxin levels may increase. (<a href="#Section_7.3">7.3</a>, <a href="#Section_7.4">7.4</a>)    </li>
<li>Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. (<a href="#Section_7.4">7.4</a>)    </li>
<li>Amiodarone may increase carvedilol levels resulting in further slowing of the heart rate or cardiac conduction. (<a href="#Section_7.6">7.6</a>)    </li>
<li>Verapamil- or diltiazem-type calcium channel blockers may affect ECG and/or blood pressure. <a href="#Section_7.7">(7.7)</a>
</li>
<li>Insulin and oral hypoglycemics action may be enhanced. <a href="#Section_7.8">(7.8)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cessation of Therapy</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>/<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">allergic Bronchospasm</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Glycemic Control in Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disease</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Deterioration of Renal Function</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Major Surgery</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Variant Angina</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Laboratory Abnormalities</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP2D6 Inhibitors and Poor Metabolizers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Hypotensive Agents</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Cyclosporine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Digitalis Glycosides</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Inducers/Inhibitors of Hepatic Metabolism</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Amiodarone</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Calcium Channel Blockers</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Insulin or Oral Hypoglycemics</a></h2>
<h2><a href="#section-7.9" class="toc">7.9  Anesthesia</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Specific Populations</a></h2>
<h2><a href="#section-11.5" class="toc">12.5 Drug-Drug Interactions</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.4  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> With Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Patient Advice</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.1"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First"><br>Carvedilol tablets, USP are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and have a left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> of ≤40% (with or without symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>) <span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-1.2"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First"><br>Carvedilol tablets, USP are indicated for the management of <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> <span class="Italics">[see <a href="#Section_14.3">Clinical Studies (14.3</a>, <a href="#Section_14.4">14.4)</a>]</span>. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics <span class="Italics">[see <a href="#Section_7.2">Drug Interactions (7.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><br>Carvedilol tablets should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.1"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First"><br>DOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION. Treatment with carvedilol tablets may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> has been minimized. It is recommended that carvedilol tablets be started at 6.25 mg twice daily and increased after 3 to 10 days, based on tolerability, to 12.5 mg twice daily, then again to the target dose of 25 mg twice daily. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> or heart rate, or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>). Patients should be maintained on lower doses if higher doses are not tolerated. The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral β-blocker during the acute phase of the <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.2"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First"><br>DOSAGE MUST BE INDIVIDUALIZED. The recommended starting dose of carvedilol tablets is 6.25 mg twice daily. If this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 12.5 mg twice daily if needed, based on trough blood pressure, again using standing systolic pressure one hour after dosing as a guide for tolerance. This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 25 mg twice daily if tolerated and needed. The full antihypertensive effect of carvedilol tablets is seen within 7 to 14 days. Total daily dose should not exceed 50 mg.<br><br>Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.3"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><br>Carvedilol tablets should not be given to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_4">Contraindications (4)</a>]</span>.  </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><br>Carvedilol tablets 3.125 mg are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘01’ on the other side. The 6.25 mg are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘02’ on the other side. The 12.5 mg are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘03’ on the other side. The 25 mg are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘04’ on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Carvedilol tablets are contraindicated in the following conditions:</p>
<p><br></p>
<ul class="Disc">
<li>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or related bronchospastic conditions. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> from status asthmaticus have been reported following single doses of carvedilol tablets.</li>
<li>Second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span></li>
<li><span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick sinus syndrome</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (unless a permanent pacemaker is in place)</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> or who have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol tablets.</li>
<li>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></li>
<li>Patients with a history of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to any component of this medication or other medications containing carvedilol.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cessation of Therapy</h2>
<p class="First"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, who are being treated with carvedilol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> have been reported in angina patients following the abrupt discontinuation of therapy with β-blockers. The last 2 complications may occur with or without preceding exacerbation of the <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. As with other β-blockers, when discontinuation of carvedilol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. Carvedilol should be discontinued over 1 to 2 weeks whenever possible. If the angina worsens or acute coronary insufficiency develops, it is recommended that carvedilol be promptly reinstituted, at least temporarily. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized, it may be prudent not to discontinue therapy with carvedilol abruptly even in patients treated only for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></h2>
<p class="First"><br>In clinical trials, carvedilol caused <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> in about 2% of hypertensive patients, and 6.5% of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>. If pulse rate drops below 55 beats/minute, the dosage should be reduced. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> occurred in 1.8% and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in 0.1% of hypertensive patients, primarily following the initial dose or at the time of dose increase and was a cause for discontinuation of therapy in 1% of patients.<br><br>In the CAPRICORN study of survivors of an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> occurred in 20.2% of patients receiving carvedilol compared to 12.6% of placebo patients. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> was reported in 3.9% and 1.9% of patients, respectively. These events were a cause for discontinuation of therapy in 2.5% of patients receiving carvedilol, compared to 0.2% of placebo patients.<br><br>Starting with a low dose, administration with food, and gradual up-titration should decrease the likelihood of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_2.2">Dosage and Administration (2.2</a>, <a href="http://pragmaticdata.com/spl/form/#Section_2.3">2.3)</a>]</span>. During initiation of therapy, the patient should be cautioned to avoid situations such as driving or hazardous tasks, where injury could result should <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>/<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> may occur during up-titration of carvedilol. If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_2">Dosage and Administration (2)</a>]</span>. Occasionally it is necessary to lower the carvedilol dose or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of, or a favorable response to, carvedilol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Non-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">allergic Bronchospasm</span></h2>
<p class="First">Patients with bronchospastic disease (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) should, in general, not receive β-blockers. Carvedilol may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. It is prudent, if carvedilol is used, to use the smallest effective dose, so that inhibition of endogenous or exogenous β-agonists is minimized.<br><br>In clinical trials of patients with bronchospastic disease were enrolled if they did not require oral or inhaled medication to treat their bronchospastic disease. In such patients, it is recommended that carvedilol be used with caution. The dosing recommendations should be followed closely and the dose should be lowered if any evidence of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> is observed during up-titration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Glycemic Control in Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">In general, β-blockers may mask some of the manifestations of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, particularly <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Nonselective β-blockers may potentiate insulin-induced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and delay recovery of serum glucose levels. Patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities.<br><br>Studies designed to examine the effects of carvedilol on glycemic control in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have not been conducted.<br><br>In a study designed to examine the effects of carvedilol on glycemic control in a population with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and well-controlled type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, carvedilol had no adverse effect on glycemic control, based on HbA1c measurements <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_14.4">Clinical Studies (14.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disease</span></h2>
<p class="First">β-blockers can precipitate or aggravate symptoms of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span> in patients with <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. Caution should be exercised in such individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Deterioration of Renal Function</h2>
<p class="First">Rarely, use of carvedilol in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> has resulted in deterioration of renal function. Patients at risk appear to be those with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> (systolic blood pressure &lt;100 mm Hg), <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> and diffuse vascular disease, and/or underlying <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Renal function has returned to baseline when carvedilol was stopped. In patients with these risk factors it is recommended that renal function be monitored during up-titration of carvedilol and the drug discontinued or dosage reduced if worsening of renal function occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Major Surgery</h2>
<p class="First">Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, <span class="XmChange">the</span> impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">β-adrenergic blockade may mask clinical signs of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or may precipitate <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, an α-blocking agent should be initiated prior to the use of any β-blocking agent. Although carvedilol has both α- and β-blocking pharmacologic activities, there has been no experience with its use in this condition. Therefore, caution should be taken in the administration of carvedilol to patients suspected of having <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Variant Angina</span></h2>
<p class="First">Agents with non-selective β-blocking activity may provoke <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> in patients with Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>. There has been no clinical experience with carvedilol in these patients although the α-blocking activity may prevent such symptoms. However, caution should be taken in the administration of carvedilol to patients suspected of having Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></h2>
<p class="First">While taking β-blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.15"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436397" conceptname="Intraoperative floppy iris syndrome">Intraoperative Floppy Iris Syndrome</span> (IFIS) has been observed during <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery in some patients treated with alpha-1 blockers (carvedilol is an alpha/beta blocker). This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, <span class="XmChange">progressive</span> intraoperative <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to the surgical technique, such as utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Carvedilol has been evaluated for safety in patients with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and in hypertensive patients. The observed adverse event profile was consistent with the pharmacology of the drug and the health status of the patients in the clinical trials. Adverse events reported for each of these patient populations are provided below. Excluded are adverse events considered too general to be informative, and those not reasonably associated with the use of the drug because they were associated with the condition being treated or are very common in the treated population. Rates of adverse events were generally similar across demographic subsets (men and women, elderly and non-elderly, blacks and non-blacks).<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span> Carvedilol has been evaluated for safety in survivors of an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> in the CAPRICORN trial which involved 969 patients who received carvedilol and 980 who received placebo. Approximately 75% of the patients received carvedilol for at least 6 months and 53% received carvedilol for at least 12 months. Patients were treated for an average of 12.9 months and 12.8 months with carvedilol and placebo, respectively.<br><br>The following adverse events were reported with a frequency of &gt;1% but ≤3% and more frequently with carvedilol: <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>. The overall rates of discontinuations due to adverse events were similar in both groups of patients. In this database, the only cause of discontinuation &gt;1%, and occurring more often on carvedilol was <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (1.5% on carvedilol, 0.2% on placebo).<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:</span> Carvedilol has been evaluated for safety in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in more than 2,193 patients in U.S. clinical trials and in 2,976 patients in international clinical trials. Approximately 36% of the total treated population received carvedilol for at least 6 months. Most adverse events reported during therapy with carvedilol were of mild to moderate severity. In U.S. controlled clinical trials directly comparing carvedilol in doses up to 50 mg (n = 1,142) to placebo (n = 462), 4.9% of patients receiving carvedilol discontinued for adverse events versus 5.2% of placebo patients. Although there was no overall difference in discontinuation rates, discontinuations were more common in the carvedilol group for <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (1% versus 0). The overall incidence of adverse events in U.S. placebo-controlled trials increased with increasing dose of carvedilol. For individual adverse events this could only be distinguished for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, which increased in frequency from 2% to 5% as total daily dose increased from 6.25 mg to 50 mg.<br><br>Table 1 shows adverse events in U.S. placebo-controlled clinical trials for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that occurred with an incidence of ≥1% regardless of causality, and that were more frequent in drug-treated patients than placebo-treated patients.</p>
<a name="i17624bfd-b596-4e39-8c9f-175fbd2a5f7f"></a><table width="100%">
<caption><span>Table 1. Adverse Events (%) Occurring in U.S. Placebo-Controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> Trials (Incidence ≥1%, Regardless of Causality)* </span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule"></th>
<th class="Lrule Rrule Toprule" align="center">Carvedilol</th>
<th class="Lrule Rrule Toprule" align="center">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">(n = 1,142)</th>
<th class="Lrule Rrule Toprule" align="center">(n = 462)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td>
<span class="Sup">*</span>Shown are events with rate &gt;1% rounded to nearest integer. </td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule"><span class="Bold">   Cardiovascular</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> </td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">—</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> </td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">—</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> </td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">—</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule"><span class="Bold">   Central Nervous System</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule"><span class="Bold">   Gastrointestinal</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule"><span class="Bold">   Hematologic</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">—</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule"><span class="Bold">   Metabolic</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">—</td>
</tr>
</tbody>
</table>
<p><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> were also reported in these studies, but the rates were equal or greater in patients who received placebo.<br><br>The following adverse events not described above were reported as possibly or probably related to carvedilol in worldwide open or controlled trials with carvedilol in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<span class="Bold"><br><br>Incidence &gt;0.1% to ≤1%</span><span class="Italics"><br><br>Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">Peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.<span class="Italics"><br><br>Central and Peripheral Nervous System: </span><span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span>.<span class="Italics"><br><br>Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Bilirubinemia</span>, increased hepatic enzymes (0.2% of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> patients were discontinued from therapy because of increases in hepatic enzymes) <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_6.2">Adverse Reactions (6.2)</a>]</span>.<span class="Italics"><br><br>Psychiatric: </span><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, impaired concentration, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">paroniria</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>.<span class="Italics"><br><br>Respiratory System: </span><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_4">Contraindications (4)</a>]</span>.<span class="Italics"><br><br>Reproductive, male: </span>Decreased libido.<span class="Italics"><br><br>Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular, <span class="product-label-link" type="condition" conceptid="4179347" conceptname="Psoriasiform dermatitis">rash psoriaform</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>.<span class="Italics"><br><br>Special Senses: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>.<span class="Italics"><br><br>Urinary System: </span>Micturition frequency increased.<span class="Italics"><br><br>Autonomic Nervous System: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>.<span class="Italics"><br><br>Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.<span class="Italics"><br><br>Hematologic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. <br><br>The following events were reported in ≤0.1% of patients and are potentially important: Complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, decreased hearing, <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>, increased BUN, decreased HDL, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and atypical <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Laboratory Abnormalities</h2>
<p class="First">Reversible elevations in serum transaminases (ALT or AST) have been observed during treatment with carvedilol. Rates of transaminase elevations (2- to 3-times the upper limit of normal) observed during controlled clinical trials have generally been similar between patients treated with carvedilol and those treated with placebo. However, transaminase elevations, confirmed by rechallenge, have been observed with carvedilol. In a long-term, placebo-controlled trial in severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, patients treated with carvedilol had lower values for hepatic transaminases than patients treated with placebo, possibly because improvements in cardiac function induced by carvedilol led to less <span class="product-label-link" type="condition" conceptid="4296301" conceptname="Hepatic congestion">hepatic congestion</span> and/or improved hepatic blood flow.<br><br>Carvedilol has not been associated with clinically significant changes in serum potassium, total triglycerides, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, uric acid, blood urea nitrogen, or creatinine. No clinically relevant changes were noted in fasting serum glucose in hypertensive patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of carvedilol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br><br>Reports of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>) have been rare and received only when carvedilol was administered concomitantly with other medications associated with such reactions. Rare reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) have been received for carvedilol tablets and carvedilol phosphate extended-release capsules, including cases occurring after the initiation of carvedilol phosphate extended-release capsules in patients previously treated with carvedilol. <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span> in women (which resolved upon discontinuation of the medication) and <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> have been reported rarely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP2D6 Inhibitors and Poor Metabolizers</h2>
<p class="First">Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>. Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the α-blocking R(+) enantiomer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Hypotensive Agents</h2>
<p class="First">Patients taking both agents with β-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.<br><br>Concomitant administration of clonidine with agents with β-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects. When concomitant treatment with agents with β-blocking properties and clonidine is to be terminated, the β-blocking agent should be discontinued first. Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Cyclosporine</h2>
<p class="First">Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection. In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed. On the average for the group, the dose of cyclosporine was reduced about 20% in these patients. Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Digitalis Glycosides</h2>
<p class="First">Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly. Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing carvedilol <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_12.5">Clinical Pharmacology (12.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Inducers/Inhibitors of Hepatic Metabolism</h2>
<p class="First">Rifampin reduced plasma concentrations of carvedilol by about 70% <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_12.5">Clinical Pharmacology (12.5)</a>]. </span>Cimetidine increased AUC by about 30% but caused no change in C<span class="Sub">max</span><span class="Italics"> [see <a href="http://pragmaticdata.com/spl/form/#Section_12.5">Clinical Pharmacology (12.5)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Amiodarone</h2>
<p class="First">Amiodarone, and its metabolite desethyl amiodarone, inhibitors of CYP2C9 and P-glycoprotein, increased concentrations of the S(-)-enantiomer of carvedilol by at least 2-fold <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_12.5">Clinical Pharmacology (12.5)</a>]</span>. The concomitant administration of amiodarone or other CYP2C9 inhibitors such as fluconazole with carvedilol may enhance the β-blocking properties of carvedilol resulting in further slowing of the heart rate or cardiac conduction. Patients should be observed for signs of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, particularly when one agent is added to pre-existing treatment with the other.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Calcium Channel Blockers</h2>
<p class="First">Conduction disturbance (rarely with hemodynamic compromise) has been observed when carvedilol is coadministered with diltiazem. As with other agents with β-blocking properties, if carvedilol is to be administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Insulin or Oral Hypoglycemics</h2>
<p class="First">Agents with β-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics. Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.9"></a><a name="section-7.9"></a><p></p>
<h2>7.9  Anesthesia</h2>
<p class="First">If treatment with carvedilol is to be continued perioperatively, particular care should be taken when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_10">Overdosage (10)</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. Studies performed in pregnant rats and rabbits given carvedilol revealed increased post-implantation loss in rats at doses of 300 mg/kg/day (50 times the maximum recommended human dose [MRHD] as mg/m<span class="Sup">2</span>) and in rabbits at doses of 75 mg/kg/day (25 times the MRHD as mg/m<span class="Sup">2</span>). In the rats, there was also a decrease in fetal body weight at the maternally toxic dose of 300 mg/kg/day (50 times the MRHD as mg/m<span class="Sup">2</span>), which was accompanied by an elevation in the frequency of fetuses with delayed skeletal development (missing or stunted 13th rib). In rats the no-observed-effect level for developmental toxicity was 60 mg/kg/day (10 times the MRHD as mg/m<span class="Sup">2</span>); in rabbits it was 15 mg/kg/day (5 times the MRHD as mg/m<span class="Sup">2</span>). There are no adequate and well-controlled studies in pregnant women. Carvedilol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Studies in rats have shown that carvedilol and/or its metabolites (as well as other β-blockers) cross the placental barrier and are excreted in breast milk. There was increased mortality at one week post-partum in neonates from rats treated with 60 mg/kg/day (10 times the MRHD as mg/m<span class="Sup">2</span>) and above during the last trimester through day 22 of lactation. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from β-blockers, especially <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The effects of other α- and β-blocking agents have included perinatal and neonatal distress.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Effectiveness of carvedilol in patients younger than 18 years of age has not been established.<br><br>In a double-blind trial, 161 children (mean age 6 years, range 2 months to 17 years; 45% less than 2 years old) with chronic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> [NYHA class II to IV, left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40% for children with a systemic left ventricle (LV), and moderate-severe ventricular dysfunction qualitatively by echo for those with a systemic ventricle that was not an LV] who were receiving standard background treatment were randomized to placebo or to 2 dose levels of carvedilol. These dose levels produced placebo-corrected heart rate reduction of 4 to 6 heart beats per minute, indicative of β-blockade activity. Exposure appeared to be lower in pediatric subjects than adults. After 8 months of follow-up, there was no significant effect of treatment on clinical outcomes. Adverse reactions in this trial that occurred in greater than 10% of patients treated with carvedilol and at twice the rate of placebo-treated patients included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (17% versus 6%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (13% versus 2%), and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (11% versus 0%).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 975 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients randomized to carvedilol in the CAPRICORN trial, 48% (468) were 65 years of age or older, and 11% (111) were 75 years of age or older.<br><br>Of the 2,065 hypertensive patients in U.S. clinical trials of efficacy or safety who were treated with carvedilol, 21% (436) were 65 years of age or older. Of 3,722 patients receiving carvedilol in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> clinical trials conducted worldwide, 24% were 65 years of age or older.<br><br>With the exception of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> in hypertensive patients (incidence 8.8% in the elderly versus 6% in younger patients), no overall differences in the safety or effectiveness (see Figure 2) were observed between the older subjects and younger subjects in each of these populations. Similarly, other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac insufficiency</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Respiratory problems, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, lapses of consciousness, and generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may also occur.<br><br>The patient should be placed in a supine position and, where necessary, kept under observation and treated under intensive-care conditions. Gastric lavage or pharmacologically induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> may be used shortly after ingestion. The following agents may be administered:<span class="Italics"><br><br>for excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>:</span> Atropine, 2 mg IV.<span class="Italics"><br><br>to support cardiovascular function:</span> Glucagon, 5 to 10 mg IV rapidly over 30 seconds, followed by a continuous infusion of 5 mg/hour; sympathomimetics (dobutamine, isoprenaline, adrenaline) at doses according to body weight and effect.<br><br>If peripheral vasodilation dominates, it may be necessary to administer adrenaline or noradrenaline with continuous monitoring of circulatory conditions. For therapy-resistant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, pacemaker therapy should be performed. For <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, β-sympathomimetics (as aerosol or IV) or aminophylline IV should be given. In the event of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, slow IV injection of diazepam or clonazepam is recommended.<br><br>NOTE: In the event of severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> where there are symptoms of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, treatment with antidotes must be continued for a sufficiently long period of time consistent with the 7- to 10-hour half-life of carvedilol.<br><br>Cases of overdosage with carvedilol alone or in combination with other drugs have been reported. Quantities ingested in some cases exceeded 1,000 milligrams. Symptoms experienced included <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> and heart rate. Standard supportive treatment was provided and individuals recovered.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><br>Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity. It is (±)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:</p>
<div class="Figure"><img alt="Carvedilol Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=carvedilol-str.jpg"></div>
<p><br>Carvedilol tablets, USP are white, oval, film-coated tablets containing 3.125 mg, 6.25 mg, 12.5 mg, or 25 mg of carvedilol. Inactive ingredients consist of lactose monohydrate, colloidal silicon dioxide, crospovidone, povidone, sucrose, magnesium stearate, polyethylene glycol 400, polysorbate 80, titanium dioxide, and hypromellose.<br><br>Carvedilol USP is a white to off-white powder with a molecular weight of 406.5 and a molecular formula of C24H26N2O4. It is freely soluble in dimethylsulfoxide; soluble in methylene chloride and methanol; sparingly soluble in 95% ethanol and isopropanol; slightly soluble in ethyl ether; and practically insoluble in water, gastric fluid (simulated, TS, pH 1.1), and intestinal fluid (simulated, TS without pancreatin, pH 7.5).<br><br>Meets USP Dissolution Test 2</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Carvedilol is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α<span class="Sub">1</span>-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activit</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span> The basis for the beneficial effects of carvedilol in patients with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> following an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> is not established.<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:</span> The mechanism by which β-blockade produces an antihypertensive effect has not been established.<br><br>β-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in normal subjects; (2) reduces exercise- and/or isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; and (3) reduces reflex orthostatic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Significant β-adrenoreceptor blocking effect is usually seen within 1 hour of drug administration.<br><br>α<span class="Sub">1</span>-adrenoreceptor blocking activity has been demonstrated in human and animal studies, showing that carvedilol (1) attenuates the pressor effects of phenylephrine; (2) causes vasodilation; and (3) reduces peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>. These effects contribute to the reduction of blood pressure and usually are seen within 30 minutes of drug administration.<br><br>Due to the α<span class="Sub">1</span>-receptor blocking activity of carvedilol, blood pressure is lowered more in the standing than in the supine position, and symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> (1.8%), including rare instances of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, can occur. Following oral administration, when <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> has occurred, it has been transient and is uncommon when carvedilol is administered with food at the recommended starting dose and titration increments are closely followed <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_2">Dosage and Administration (2)</a>]</span>.<br><br>In hypertensive patients with normal renal function, therapeutic doses of carvedilol decreased renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> with no change in glomerular filtration rate or renal plasma flow. Changes in excretion of sodium, potassium, uric acid, and phosphorus in hypertensive patients with normal renal function were similar after carvedilol and placebo.<br><br>Carvedilol has little effect on plasma catecholamines, plasma aldosterone, or electrolyte levels, but it does significantly reduce plasma renin activity when given for at least 4 weeks. It also increases levels of atrial natriuretic peptide.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism. Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. Plasma concentrations achieved are proportional to the oral dose administered. When administered with food, the rate of absorption is slowed, as evidenced by a delay in the time to reach peak plasma levels, with no significant difference in extent of bioavailability. Taking carvedilol with food should minimize the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.<br><br>Carvedilol is extensively metabolized. Following oral administration of radiolabelled carvedilol to healthy volunteers, carvedilol accounted for only about 7% of the total radioactivity in plasma as measured by area under the curve (AUC). Less than 2% of the dose was excreted unchanged in the urine. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the feces. Demethylation and hydroxylation at the phenol ring produce 3 active metabolites with β-receptor blocking activity. Based on preclinical studies, the 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for β-blockade.<br><br>Compared to carvedilol, the 3 active metabolites exhibit weak vasodilating activity. Plasma concentrations of the active metabolites are about one-tenth of those observed for carvedilol and have pharmacokinetics similar to the parent.<br><br>Carvedilol undergoes stereoselective first-pass metabolism with plasma levels of R(+)-carvedilol approximately 2 to 3 times higher than S(-)-carvedilol following oral administration in healthy subjects. The mean apparent terminal elimination half-lives for R(+)-carvedilol range from 5 to 9 hours compared with 7 to 11 hours for the S(-)-enantiomer.<br><br>The primary P450 enzymes responsible for the metabolism of both R(+) and S(-)-carvedilol in human liver microsomes were CYP2D6 and CYP2C9 and to a lesser extent CYP3A4, 2C19, 1A2, and 2E1. CYP2D6 is thought to be the major enzyme in the 4’- and 5’-hydroxylation of carvedilol, with a potential contribution from 3A4. CYP2C9 is thought to be of primary importance in the O-methylation pathway of S(-)-carvedilol.<br><br>Carvedilol is subject to the effects of genetic polymorphism with poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) exhibiting 2- to 3-fold higher plasma concentrations of R(+)-carvedilol compared to extensive metabolizers. In contrast, plasma levels of S(-)-carvedilol are increased only about 20% to 25% in poor metabolizers, indicating this enantiomer is metabolized to a lesser extent by cytochrome P450 2D6 than R(+)-carvedilol. The pharmacokinetics of carvedilol do not appear to be different in poor metabolizers of S-mephenytoin (patients deficient in cytochrome P450 2C19).<br><br>Carvedilol is more than 98% bound to plasma proteins, primarily with albumin. The plasma-protein binding is independent of concentration over the therapeutic range. Carvedilol is a basic, lipophilic compound with a steady-state volume of distribution of approximately 115 L, indicating substantial distribution into extravascular tissues. Plasma clearance ranges from 500 to 700 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Specific Populations</h2>
<p class="First"><span class="Underline">Geriatric:</span> Plasma levels of carvedilol average about 50% higher in the elderly compared to young subjects.<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Compared to healthy subjects, patients with severe liver impairment (cirrhosis) exhibit a 4- to 7-fold increase in carvedilol levels. Carvedilol is contraindicated in patients with severe liver impairment.<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Although carvedilol is metabolized primarily by the liver, plasma concentrations of carvedilol have been reported to be increased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Based on mean AUC data, approximately 40% to 50% higher plasma concentrations of carvedilol were observed in hypertensive patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared to a control group of hypertensive patients with normal renal function. However, the ranges of AUC values were similar for both groups. Changes in mean peak plasma levels were less pronounced, approximately 12% to 26% higher in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.<br><br>Consistent with its high degree of plasma protein-binding, carvedilol does not appear to be cleared significantly by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.5"></a><a name="section-11.5"></a><p></p>
<h2>12.5 Drug-Drug Interactions</h2>
<p class="First">Since carvedilol undergoes substantial oxidative metabolism, the metabolism and pharmacokinetics of carvedilol may be affected by induction or inhibition of cytochrome P450 enzymes.<br><br><span class="Underline">Amiodarone:</span> In a pharmacokinetic study conducted in 106 Japanese patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, coadministration of small loading and maintenance doses of amiodarone with carvedilol resulted in at least a 2-fold increase in the steady-state trough concentrations of S(-)-carvedilol <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_7.6">Drug Interactions (7.6)</a>]</span>.<br><br><span class="Underline">Cimetidine:</span> In a pharmacokinetic study conducted in 10 healthy male subjects, cimetidine (1,000 mg/day) increased the steady-state AUC of carvedilol by 30% with no change in C<span class="Sub">max</span><span class="Italics"> [see <a href="http://pragmaticdata.com/spl/form/#Section_7.5">Drug Interactions (7.5)</a></span><span class="Italics">]</span>.<br><br><span class="Underline">Digoxin:</span> Following concomitant administration of carvedilol (25 mg once daily) and digoxin (0.25 mg once daily) for 14 days, steady-state AUC and trough concentrations of digoxin were increased by 14% and 16%, respectively, in 12 hypertensive patients <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_7.4">Drug Interactions (7.4)</a>]</span>.<br><br><span class="Underline">Glyburide:</span> In 12 healthy subjects, combined administration of carvedilol (25 mg once daily) and a single dose of glyburide did not result in a clinically relevant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> for either compound.<br><br><span class="Underline">Hydrochlorothiazide:</span> A single oral dose of carvedilol 25 mg did not alter the pharmacokinetics of a single oral dose of hydrochlorothiazide 25 mg in 12 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Likewise, hydrochlorothiazide had no effect on the pharmacokinetics of carvedilol.<br><br><span class="Underline">Rifampin:</span> In a pharmacokinetic study conducted in 8 healthy male subjects, rifampin (600 mg daily for 12 days) decreased the AUC and C<span class="Sub">max </span>of carvedilol by about 70% <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_7.5">Drug Interactions (7.5)</a>]</span>.<br><br><span class="Underline">Torsemide:</span> In a study of 12 healthy subjects, combined oral administration of carvedilol 25 mg once daily and torsemide 5 mg once daily for 5 days did not result in any significant differences in their pharmacokinetics compared with administration of the drugs alone.<br><br><span class="Underline">Warfarin:</span> Carvedilol (12.5 mg twice daily) did not have an effect on the steady-state <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time ratios and did not alter the pharmacokinetics of R(+)- and S(-)-warfarin following concomitant administration with warfarin in 9 healthy volunteers.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In 2-year studies conducted in rats given carvedilol at doses up to 75 mg/kg/day (12 times the MRHD when compared on a mg/m<span class="Sup">2</span> basis) or in mice given up to 200 mg/kg/day (16 times the MRHD on a mg/m<span class="Sup">2</span> basis), carvedilol had no carcinogenic effect.<br><br>Carvedilol was negative when tested in a battery of genotoxicity assays, including the Ames and the CHO/HGPRT assays for mutagenicity and the <span class="Italics">in vitro</span> hamster micronucleus and <span class="Italics">in vivo</span> human lymphocyte cell tests for clastogenicity.<br><br>At doses ≥200 mg/kg/day (≥32 times the MRHD as mg/m<span class="Sup">2</span>) carvedilol was toxic to adult rats (sedation, reduced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) and was associated with a reduced number of successful matings, prolonged mating time, significantly fewer corpora lutea and implants per dam, and complete resorption of 18% of the litters. The no-observed-effect dose level for overt toxicity and impairment of fertility was 60 mg/kg/day (10 times the MRHD as mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.1"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span> Following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">CAPRICORN was a double-blind study comparing carvedilol and placebo in 1,959 patients with a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (within 21 days) and left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> of ≤40%, with (47%) or without symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients given carvedilol received 6.25 mg twice daily, titrated as tolerated to 25 mg twice daily. Patients had to have a systolic blood pressure &gt;90 mm Hg, a sitting heart rate &gt;60 beats/minute, and no contraindication to β-blocker use. Treatment of the index <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> included aspirin (85%), IV or oral β-blockers (37%), nitrates (73%), heparin (64%), thrombolytics (40%), and acute angioplasty (12%). Background treatment included ACE inhibitors or angiotensin receptor blockers (97%), anticoagulants (20%), lipid-lowering agents (23%), and diuretics (34%). Baseline population characteristics included an average age of 63 years, 74% male, 95% Caucasian, mean blood pressure 121/74 mm Hg, 22% with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and 54% with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Mean dosage achieved of carvedilol was 20 mg twice daily; mean duration of follow-up was 15 months.<br><br>All-cause mortality was 15% in the placebo group and 12% in the carvedilol group, indicating a 23% risk reduction in patients treated with carvedilol (95% CI 2 to 40%, p = 0.03), as shown in Figure 1. The effects on mortality in various subgroups are shown in Figure 2. Nearly all <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were cardiovascular (which were reduced by 25% by carvedilol), and most of these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were sudden or related to pump failure (both types of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were reduced by carvedilol). Another study end point, total mortality and all-cause hospitalization, did not show a significant improvement.<br><br>There was also a significant 40% reduction in fatal or non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> observed in the group treated with carvedilol (95% CI 11% to 60%, p = 0.01). A similar reduction in the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was also observed in a meta-analysis of placebo-controlled trials of carvedilol in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<div class="Figure"><img alt="Figure 1. Survival Analysis for CAPRICORN (intent-to-treat)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=carvedilol-fig1.jpg"></div>
<p><br><span class="Bold">Figure 1. Survival Analysis for CAPRICORN (intent-to-treat)</span></p>
<div class="Figure"><img alt="Figure 2. Effects on Mortality for Subgroups in CAPRICORN" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=carvedilol-fig2.jpg"></div>
<p><br><span class="Bold">Figure 2. Effects on Mortality for Subgroups in CAPRICORN</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.2"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Carvedilol was studied in 2 placebo-controlled trials that utilized twice-daily dosing, at total daily doses of 12.5 to 50 mg. In these and other studies, the starting dose did not exceed 12.5 mg. At 50 mg/day, carvedilol reduced sitting trough (12-hour) blood pressure by about 9/5.5 mm Hg; at 25 mg/day the effect was about 7.5/3.5 mm Hg. Comparisons of trough to peak blood pressure showed a trough to peak ratio for blood pressure response of about 65%. Heart rate fell by about 7.5 beats/minute at 50 mg/day. In general, as is true for other β-blockers, responses were smaller in black than non-black patients. There were no age- or gender-related differences in response.<br><br>The peak antihypertensive effect occurred 1 to 2 hours after a dose. The dose-related blood pressure response was accompanied by a dose-related increase in adverse effects</p>
<p><span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_6">Adverse Reactions (6)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.4"></a><a name="section-13.3"></a><p></p>
<h2>14.4  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> With Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">In a double-blind study (GEMINI), carvedilol, added to an ACE inhibitor or angiotensin receptor blocker, was evaluated in a population with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and well-controlled type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. The mean HbA1c at baseline was 7.2%. Carvedilol was titrated to a mean dose of 17.5 mg twice daily and maintained for 5 months. Carvedilol had no adverse effect on glycemic control, based on HbA1c measurements (mean change from baseline of 0.02%, 95% CI -0.06 to 0.1, p = NS) <span class="Italics">[see <a href="http://pragmaticdata.com/spl/form/#Section_5.6">Warnings and Precautions (5.6)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_18"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Carvedilol Tablets USP, 3.125 mg</span> are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘01’ on the other side.<br><br>         Bottles of 100               NDC 65862-142-01<br>         Bottles of 500               NDC 65862-142-05<br>         Bottles of 1000             NDC 65862-142-99<span class="Bold"><br><br>Carvedilol Tablets USP, 6.25 mg </span>are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘02’ on the other side.  <br><br>         Bottles of 100               NDC 65862-143-01<br>         Bottles of 500               NDC 65862-143-05<br>         Bottles of 1000             NDC 65862-143-99<span class="Bold"><br><br>Carvedilol Tablets USP, 12.5 mg </span>are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘03’ on the other side. <br><br>         Bottles of 100               NDC 65862-144-01 <br>         Bottles of 500               NDC 65862-144-05<br>         Bottles of 1000             NDC 65862-144-99<span class="Bold"><br><br>Carvedilol Tablets USP, 25 mg </span>are white to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘04’ on the other side.  <br><br>         Bottles of 100               NDC 65862-145-01<br>         Bottles of 500               NDC 65862-145-05<br>         Bottles of 1000             NDC 65862-145-99<br><span class="Bold"><br>Store at</span> 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling <a href="http://pragmaticdata.com/spl/form/#Section_19">(17.2)</a>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Patient Advice</h2>
<p class="First">Patients taking carvedilol should be advised of the following:<br></p>
<ul class="Disc">
<li>Patients should take carvedilol with food.</li>
<li>Patients should not interrupt or discontinue using carvedilol without a physician’s advice.</li>
<li>Patients should consult their physician if they experience signs or symptoms of worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> such as <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or increasing <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</li>
<li>Patients may experience a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> when standing, resulting in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and, rarely, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. Patients should sit or lie down when these symptoms of <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">lowered blood pressure</span> occur.</li>
<li>If experiencing <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, patients should avoid driving or hazardous tasks.</li>
<li>Patients should consult a physician if they experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or faintness, in case the dosage should be adjusted.</li>
<li>Diabetic patients should report any changes in blood sugar levels to their physician.</li>
<li>Contact lens wearers may experience decreased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_19"></a><a name="section-16"></a><p></p>
<h1>17.2   FDA-Approved Patient Labeling</h1>
<p class="First"><span class="Bold">PATIENT INFORMATION<br>Carvedilol Tablets, USP</span><br><br>Read the Patient Information that comes with carvedilol tablets before you start taking them and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about carvedilol tablets, ask your doctor or pharmacist.</p>
<p><span class="Bold"><br>What are carvedilol tablets?</span><br><br>Carvedilol tablets are a prescription medicine that belongs to a group of medicines called “beta-blockers?.<br><br>Carvedilol tablets are used, often with other medicines, for the following conditions:<br></p>
<ul class="Disc">
<li>To treat patients who had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> that worsened how well the heart pumps</li>
<li>To treat patients with high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)</li>
</ul>
<p><br>Carvedilol tablets are not approved for use in children under 18 years of age.<br><span class="Bold"><br>Who should not take carvedilol tablets?</span><br>Do not take carvedilol tablets if you:<br></p>
<ul class="Disc">
<li>Have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and are hospitalized in the intensive care unit or require certain intravenous medications that help support circulation (inotropic medications)</li>
<li>Are prone to <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other breathing problems</li>
<li>Have a slow heartbeat or a heart that skips a beat (irregular heartbeat)</li>
<li>Have liver problems</li>
<li>Are allergic to any of the ingredients in carvedilol tablets. The active ingredient is carvedilol. See the end of this leaflet for a list of all the ingredients in carvedilol tablets.</li>
</ul>
<p><br><span class="Bold">What should I tell my doctor before taking carvedilol tablets?</span><br>Tell your doctor about all of your medical conditions, including if you:<br></p>
<ul class="Disc">
<li>Have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other lung problems (such as <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>)</li>
<li>Have problems with blood flow in your feet and legs (<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>) carvedilol tablets can make some of your symptoms worse.</li>
<li>Have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>Have thyroid problems</li>
<li>Have a condition called <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span></li>
<li>Have had severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>Are pregnant or trying to become pregnant. It is not known if carvedilol tablets are safe for your unborn baby. You and your doctor should talk about the best way to control your high blood pressure during pregnancy.</li>
<li>Are breastfeeding. It is not known if carvedilol passes into your breast milk. You should not breastfeed while using carvedilol tablets.</li>
<li>Are scheduled for surgery and will be given anesthetic agents</li>
<li>Are scheduled for <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery and have taken or are currently taking carvedilol tablets.</li>
<li>Are taking prescription or non-prescription medicines, vitamins, and herbal supplements. Carvedilol tablets and certain other medicines can affect each other and cause serious side effects. Carvedilol tablets may affect the way other medicines work. Also, other medicines may affect how well carvedilol tablets work.</li>
</ul>
<p><br>Keep a list of all the medicines you take. Show this list to your doctor and pharmacist before you start a new medicine.<br><span class="Bold"><br>How should I take carvedilol tablets?<br></span><span class="Bold">It is important for you to take your medicine every day as directed by your doctor. If you stop taking carvedilol tablets suddenly, you could have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> and/or a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.  If your doctor decides that you should stop taking carvedilol tablets, your doctor may slowly lower your dose over a period of time before stopping them completely.</span><br></p>
<ul class="Disc">
<li>Take carvedilol tablets exactly as prescribed. Your doctor will tell you how many tablets to take and how often. In order to minimize possible side effects, your doctor might begin with a low dose and then slowly increase the dose.</li>
<li><span class="Bold">Do not stop taking carvedilol tablets and do not change the amount of carvedilol tablets you take without talking to your doctor.</span></li>
<li>Tell your doctor if you gain weight or have trouble breathing while taking carvedilol tablets.</li>
<li>Take carvedilol tablets with food.</li>
<li>If you miss a dose of carvedilol tablets, take your dose as soon as you remember, unless it is time to take your next dose. Take your next dose at the usual time. Do not take 2 doses at the same time.</li>
<li>If you take too much carvedilol, call your doctor or poison control center right away.</li>
</ul>
<p><br><span class="Bold">What should I avoid while taking carvedilol tablets?</span><br><br>Carvedilol tablets can cause you to feel dizzy, tired, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>. Do not drive a car, use machinery, or do anything that needs you to be alert if you have these symptoms.<br><span class="Bold"><br>What are possible side effects of carvedilol tablets?</span><br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (which may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> when you stand up). If these happen, sit or lie down right away and tell your doctor.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span>.</span> If you feel tired or dizzy you should not drive, use machinery, or do anything that needs you to be alert.</li>
<li>Slow heartbeat.</li>
<li>Changes in your blood sugar. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, tell your doctor if you have any changes in your blood sugar levels.</li>
<li>Carvedilol tablets may hide some of the symptoms of low blood sugar, especially a fast heartbeat.</li>
<li>Carvedilol tablets may mask the symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> (overactive thyroid).</li>
<li>Worsening of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</li>
<li>Rare but serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing) have happened in patients who were on carvedilol tablets. These reactions can be life-threatening.</li>
</ul>
<p><br>Other side effects of carvedilol tablets include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and fewer tears or <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span> that become bothersome if you wear contact lenses. <br><br>Call your doctor if you have any side effects that bother you or don’t go away.<br><span class="Bold"><br>How should I store carvedilol tablets?</span><br></p>
<ul class="Disc">
<li>Store carvedilol tablets at 20 to 25°C (68 to 77°F). Keep the tablets dry.</li>
<li>Safely, throw away carvedilol tablets that are out of date or no longer needed.</li>
<li>Keep carvedilol tablets and all medicines out of the reach of children.</li>
</ul>
<p><br><span class="Bold">General information about carvedilol tablets</span><br><br>Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use carvedilol tablets for a condition for which it was not prescribed. Do not give carvedilol tablets to other people, even if they have the same symptoms you have. They may harm them.<br><br>This leaflet summarizes the most important information about carvedilol tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about carvedilol tablets that is written for healthcare professionals. You can also find out more about carvedilol tablets by calling 1-866-850-2876. This call is free.<span class="Bold"><br><br>What are the ingredients in carvedilol tablets?<br></span>Active Ingredient: Carvedilol.<br><br>Inactive Ingredients: lactose monohydrate, colloidal silicon dioxide, crospovidone, povidone, sucrose, magnesium stearate, polyethylene glycol 400, polysorbate 80, titanium dioxide, and hypromellose.<br><br>Carvedilol tablets come in the following strengths: 3.125 mg, 6.25 mg, 12.5 mg, or 25 mg.<span class="Bold"><span class="Bold"><br><br>What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?<br></span></span>Blood pressure is the force of blood in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. High blood pressure makes the heart work harder to pump blood through the body and causes damage to blood vessels. Carvedilol tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower blood pressure may lower your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.<br><br><br>Manufactured by:<br><span class="Bold">Aurolife Pharma LLC</span><br>Dayton, NJ 08810<br><br> Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.</span><br>Dayton, NJ 08810<br><br>Revised: 04/2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_26"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL</h1>
<br><p class="First"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=Carvedilol3.125mg.jpg"></p>
<br><p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=Carvedilol6.25mg.jpg"></p>
<br><p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=Carvedilol12.5mg.jpg"></p>
<p><br></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c3f7f2f7-7309-4825-b868-13c6ef89fe86&amp;name=Carvedilol25mg.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARVEDILOL
                 		
					</strong><br><span class="contentTableReg">carvedilol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60760-142(NDC:13107-142)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARVEDILOL</strong> (CARVEDILOL) </td>
<td class="formItem">CARVEDILOL</td>
<td class="formItem">3.125 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E;01</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60760-142-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60760-142-98</td>
<td class="formItem">180  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078332</td>
<td class="formItem">04/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARVEDILOL
                 		
					</strong><br><span class="contentTableReg">carvedilol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60760-143(NDC:13107-143)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARVEDILOL</strong> (CARVEDILOL) </td>
<td class="formItem">CARVEDILOL</td>
<td class="formItem">6.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E;02</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60760-143-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60760-143-98</td>
<td class="formItem">180  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078332</td>
<td class="formItem">04/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARVEDILOL
                 		
					</strong><br><span class="contentTableReg">carvedilol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60760-144(NDC:13107-144)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARVEDILOL</strong> (CARVEDILOL) </td>
<td class="formItem">CARVEDILOL</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E;03</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60760-144-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60760-144-98</td>
<td class="formItem">180  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078332</td>
<td class="formItem">04/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARVEDILOL
                 		
					</strong><br><span class="contentTableReg">carvedilol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60760-145(NDC:13107-145)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARVEDILOL</strong> (CARVEDILOL) </td>
<td class="formItem">CARVEDILOL</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E;04</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60760-145-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60760-145-98</td>
<td class="formItem">180  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078332</td>
<td class="formItem">04/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>St Marys Medical Park Pharmacy
							(063050751)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">St Marys Medical Park Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">063050751</td>
<td class="formItem">relabel(60760-142, 60760-143, 60760-144, 60760-145), repack(60760-142, 60760-143, 60760-144, 60760-145)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurolife Pharma LLC</td>
<td class="formItem"></td>
<td class="formItem">829084461</td>
<td class="formItem">manufacture(60760-142, 60760-143, 60760-144, 60760-145)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a78494c6-e60b-40c0-8cd0-8667b7c875b4</div>
<div>Set id: c3f7f2f7-7309-4825-b868-13c6ef89fe86</div>
<div>Version: 2</div>
<div>Effective Time: 20141014</div>
</div>
</div> <div class="DistributorName">St Marys Medical Park Pharmacy</div></p>
</body></html>
